STOCK TITAN

Olink Holding AB (publ) - OLK STOCK NEWS

Welcome to our dedicated page for Olink Holding AB (publ) news (Ticker: OLK), a resource for investors and traders seeking the latest updates and insights on Olink Holding AB (publ) stock.

Olink Holding AB (publ) (Nasdaq: OLK) is a pioneering company in the field of proteomics, dedicated to accelerating scientific discoveries through its innovative Proximity Extension Assay (PEA) technology. Since its founding in 2016, Olink has been at the forefront of proteomics research, providing products and services designed to enhance the understanding of real-time human biology across multiple disease areas. The company’s platform is utilized by major biopharmaceutical firms, clinical institutions, and academic researchers globally.

Olink’s proprietary PEA technology is a versatile tool that enables researchers to conduct studies spanning from initial discovery to clinical trials and even diagnostic applications. This technology leverages existing lab infrastructure and installed instrumentation, making it a highly efficient and scalable solution.

Olink operates through two main segments: Kit and Services. In the Kit segment, the company provides reagents and consumables that researchers can use in their own laboratories. The Services segment offers access to Olink’s technology through its own labs, delivering high-quality data and insights to clients worldwide.

The company is headquartered in Uppsala, Sweden, and has a significant presence in Europe, North America, and Asia. Key revenue is generated from the United States, followed by Sweden, China, EMEA (excluding Sweden), Japan, and other regions. This geographical diversity emphasizes Olink’s global impact and reach.

Olink has recently garnered attention through several strategic initiatives and developments. Notably, on March 20, 2024, Thermo Fisher Scientific received clearance from the Swedish Inspectorate of Strategic Products for a proposed transaction with Olink, expected to be completed by mid-2024. This collaboration is anticipated to further strengthen Olink's capabilities and market presence.

Investor Contacts:
Jan Medina, CFA
VP Investor Relations & Capital Markets
Mobile: +1 617 802 4157
Email: jan.medina@olink.com

Media Contacts:
Michael B. Gonzales, PhD
VP Global Marketing
Mobile: +1 415 308 6467
Email: michael.gonzales@olink.com

Rhea-AI Summary

Olink Holding AB has announced an Extra General Meeting (EGM) scheduled for August 6, 2024, at 4:00 p.m. CEST in Uppsala, Sweden. Shareholders must register by July 31, 2024, and be listed in Euroclear Sweden AB's share register by July 29, 2024, to participate. The meeting will cover the election of a new Chairman and Board members, with Anthony Smith proposed as Chairman. Electronic participation will be available, subject to approval. Proxy voting is allowed, with forms accessible online from July 16, 2024. The agenda includes voting on the number of Board members, their remuneration, and electing Board members. Olink has 124,739,269 shares, equating to the same number of votes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

Thermo Fisher Scientific (NYSE: TMO) has successfully completed its acquisition of Olink Holding AB (Nasdaq: OLK) for $3.1 billion. This strategic acquisition enhances Thermo Fisher's capabilities in the high-growth proteomics market, integrating Olink’s advanced proteomics solutions with Thermo Fisher's mass spectrometry and life sciences offerings.

The transaction was executed via a tender offer where Thermo Fisher's subsidiary, Orion Acquisition AB, acquired approximately 98.2% of Olink’s outstanding shares at $26.00 per share or ADS. The initial offering period expired on July 9, 2024, and a subsequent offering period will run until July 16, 2024.

Post-acquisition, Olink will be delisted from Nasdaq and deregistered, affecting the liquidity of remaining ADSs. Thermo Fisher aims to expedite scientific breakthroughs and deliver significant shareholder value through this acquisition.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Olink Holding AB (Nasdaq: OLK) announced that the UK Competition and Markets Authority (CMA) has unconditionally approved the tender offer by Orion Acquisition, a subsidiary of Thermo Fisher Scientific (NYSE: TMO), for all outstanding shares of Olink at $26.00 per share. The offer follows a Purchase Agreement from October 17, 2023. With CMA's approval, Olink and Thermo Fisher plan to complete the offer promptly after its expiration on July 9, 2024, at 5:00 p.m. ET. The offer is subject to conditions, including that the Buyer must hold more than 90% of the issued and outstanding common shares at the expiration time.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.93%
Tags
Rhea-AI Summary

On July 5, 2024, Olink Holding AB held an Extra General Meeting (EGM) in Uppsala, Sweden. During the meeting, several resolutions were adopted, including a decision to provide additional compensation to the board of directors. This compensation, proposed by the majority shareholder, amounts to USD 127,504 and will be distributed in tranches over multiple years. The details of these resolutions are available on the company's website.

For further information, investors can reach out to David Deuchler of the Gilmartin Group or Michael B. Gonzales, VP of Global Marketing, using the provided contact details.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.93%
Tags
none
-
Rhea-AI Summary

Olink Holding has launched its first-ever network of Olink Certified Service Providers, encompassing leading CROs and service labs worldwide. These certified providers have undergone rigorous training, testing, and re-certification to ensure top-notch performance using Olink's advanced proteomics technology.

Mike Irwin, Olink's Vice President, emphasized the goal of democratizing proteomics, making their platform accessible to researchers globally. The network includes prominent organizations such as AssayGate, Australian Genome Research Facility, and Vanderbilt University Medical Center, among others, facilitating convenient, high-quality access to Olink's cutting-edge solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.08%
Tags
none
-
Rhea-AI Summary

Olink Holding AB (publ) has announced an Extra General Meeting scheduled for July 5, 2024, at Salagatan 16A, Uppsala. Registration starts at 3:30 p.m. CET. Shareholders must be registered by Euroclear Sweden AB by June 27, 2024, and notify their attendance by July 1, 2024. Electronic participation is possible if pre-approved, but such participants must vote through a proxy attending in person. Key agenda items include electing a meeting chairman, approving the agenda, and deciding on board member fees. The majority shareholder proposes additional fees for board members, totaling USD 127,504 until the 2028 AGM, with varied amounts payable upon a change of control. Olink has 124,739,269 shares and votes in total. Shareholders can request meeting-related information as specified under Swedish law.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.24%
Tags
conferences
Rhea-AI Summary

Olink Holding AB (Nasdaq: OLK) has launched the Olink Target 48 Immune Surveillance panel. This validated multiplexed protein assay panel provides an in-depth analysis of the immune system, monitoring inflammation and immune response using only 1μL of sample. When combined with the Olink Target 48 Cytokine panel, it can detect up to 89 immune-related proteins using just 2μL of sample. The panel uses Olink’s PEA™ technology and offers precise, quantitative data, aiding research in immunology, immuno-oncology, and infectious diseases. It aims to reduce import barriers and is compatible with the Olink Signature Q100 benchtop system.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.2%
Tags
none
-
Rhea-AI Summary

Olink Holding AB (Nasdaq: OLK) announced a breakthrough study using its Olink Explore platform, showing proteins in blood may indicate cancer up to 7 years before diagnosis. Published in Nature Communications, the study analyzed blood from over 44,000 people, identifying 371 proteins associated with 19 cancers, including 107 detectable years before cancer onset. Conducted by Oxford Population Health and funded by Cancer Research UK, the findings highlight proteomics' potential for early cancer detection and better treatment. Further research is needed to confirm these proteins' roles in cancer. The study's details will be presented at the European Society of Human Genetics conference in Berlin, June 1-4.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.08%
Tags
none
-
Rhea-AI Summary

Olink Holding AB (publ) announced its first quarter 2024 financial results, showing revenue growth of 5% year over year to $28.8 million. Explore customer installations reached 121, and Signature Q100 placements reached 202. Net loss for the quarter was $(16.1) million, with adjusted EBITDA of $(15.5) million. Thermo Fisher Scientific acquisition expected to be completed by mid-2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.81%
Tags
Rhea-AI Summary
The Annual General Meeting of Olink Holding AB (publ) on April 19, 2024, adopted resolutions including approving balance sheets, remuneration to the Board of Directors, re-election of Board Members and auditor, incentive programs, and authorization for new share issues.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.73%
Tags
none

FAQ

What does Olink Holding AB specialize in?

Olink Holding AB specializes in accelerating proteomics research through its proprietary Proximity Extension Assay (PEA) technology.

What are the main segments of Olink's operations?

Olink operates through two main segments: Kit, providing reagents for labs, and Services, offering data through Olink's labs.

Where is Olink Holding AB headquartered?

Olink Holding AB is headquartered in Uppsala, Sweden.

Which markets generate the most revenue for Olink?

The United States generates the most revenue for Olink, followed by Sweden, China, EMEA (excluding Sweden), Japan, and other regions.

What is Olink's Proximity Extension Assay (PEA) technology?

PEA is a patented technology that enables research across discovery, clinical trials, and diagnostic applications, using existing lab infrastructure.

Who are the key contacts for investors and media at Olink?

Investor contact: Jan Medina, CFA (jan.medina@olink.com). Media contact: Michael B. Gonzales, PhD (michael.gonzales@olink.com).

What recent strategic developments has Olink been involved in?

Olink has been involved in a proposed transaction with Thermo Fisher Scientific, expected to be completed by mid-2024.

When was Olink Holding AB founded?

Olink Holding AB was founded in 2016.

What industries benefit from Olink's services?

Biopharmaceutical companies, clinical institutions, and academic researchers benefit from Olink's proteomics services.

How can researchers use Olink's products?

Researchers can use Olink's products through the Kit segment in their labs or access services via Olink's own labs for high-quality data.

Olink Holding AB (publ)

Nasdaq:OLK

OLK Rankings

OLK Stock Data

3.24B
124.34M
66.41%
35.25%
2.03%
Analytical Laboratory Instrument Manufacturing
Manufacturing
Link
United States of America
Uppsala